PBS Changes From 1 May 2024 miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Phase 3b results show risankizumab is superior for endoscopic remission and clinical remission at week 48 compared with ustekinumab, a "once in a career" result, study authors say.
Risankizumab (Skyrizi) was found to significantly improve clinical outcomes in patients with moderate plaque psoriasis compared with apremilast (Otezla).
The results of the INSPIRE trial demonstrated that 20.3% of individuals receiving risankizumab (Skyrizi) achieved clinical remission compared to 6.2% of individuals who received the placebo.